{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:17:09Z","timestamp":1792376229341,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003279.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000}}],"reference-count":43,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003279.pub3","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T18:32:10Z","timestamp":1296844330000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Treatment for Lambert-Eaton myasthenic syndrome"],"prefix":"10.1002","author":[{"given":"Michael","family":"Keogh","sequence":"first","affiliation":[{"name":"Newcastle University; Institute of Human Genetics, Centre for Life; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saam","family":"Sedehizadeh","sequence":"additional","affiliation":[{"name":"Queen's Medical Centre; Department of Neurology, D Floor, West Block; Derby Road Nottingham UK NG7 2UH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maddison","sequence":"additional","affiliation":[{"name":"Queen's Medical Centre; Department of Neurology, D Floor, West Block; Derby Road Nottingham UK NG7 2UH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD003279.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003279.pub3-BIB0002|cit2","first-page":"122","article-title":"3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"24","author":"McEvoy","year":"1988","journal-title":"Annals of Neurology"},{"issue":"23","key":"10.1002\/14651858.CD003279.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003279.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4 - Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle and Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003279.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003279.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.","volume":"86","author":"Wirtz","year":"July 2009","journal-title":"Clinical Pharmacology and Therpautics"},{"issue":"9","key":"10.1002\/14651858.CD003279.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.1139","article-title":"Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement","volume":"24","author":"AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine","year":"2001","journal-title":"Muscle and Nerve"},{"issue":"9","key":"10.1002\/14651858.CD003279.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mus.1140","article-title":"Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome","volume":"24","author":"AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine","year":"2001","journal-title":"Muscle and Nerve"},{"issue":"4","key":"10.1002\/14651858.CD003279.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/bja\/50.4.383","article-title":"Effects of 4-aminopyridine in Eaton Lambert Syndrome","volume":"50","author":"Agoston","year":"1978","journal-title":"British Journal of Anaesthesia"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"10.1002\/14651858.CD003279.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0012|cit12","unstructured":"BioMarin Europe Ltd Summary of Product Characteristics. Firdapse \u00ae (amifampridine) Date of revision of the text February 2010"},{"issue":"7","key":"10.1002\/14651858.CD003279.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"issue":"6066","key":"10.1002\/14651858.CD003279.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/bmj.1.6066.946-a","article-title":"Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome","volume":"1","author":"Blumhardt","year":"1977","journal-title":"British Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD003279.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle and Nerve"},{"issue":"24","key":"10.1002\/14651858.CD003279.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1073\/pnas.80.24.7636","article-title":"Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones","volume":"80","author":"Fukunaga","year":"1983","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0017|cit17","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD003279.pub3-BIB0018|cit18","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"187","author":"Lambert","year":"1956","journal-title":"American Journal of Physiology"},{"issue":"1","key":"10.1002\/14651858.CD003279.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.1966.tb45484.x","article-title":"Defects of neuromuscular transmission in syndromes other than myasthenia gravis","volume":"135","author":"Lambert","year":"1966","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","article-title":"Quantal components of end-plate potentials in the myasthenic syndrome","volume":"183","author":"Lambert","year":"1971","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8240","key":"10.1002\/14651858.CD003279.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","article-title":"Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome","volume":"2","author":"Lang","year":"1981","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.1983.sp014943","article-title":"Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse","volume":"344","author":"Lang","year":"1983","journal-title":"Journal of Physiology"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1113\/jphysiol.1987.sp016698","article-title":"The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse","volume":"390","author":"Lang","year":"1987","journal-title":"Journal of Physiology"},{"issue":"5","key":"10.1002\/14651858.CD003279.pub3-BIB0024|cit24","first-page":"345","article-title":"Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture)","volume":"26","author":"Lechat","year":"1968","journal-title":"Annales Pharmaceutiques Francaises"},{"issue":"5","key":"10.1002\/14651858.CD003279.pub3-BIB0025|cit25","first-page":"927","article-title":"Pharmacological approach to the study of convulsive action mechanism of amino-4 pyridine","volume":"26","author":"Lemeignan","year":"1971","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0026|cit26","first-page":"222","article-title":"The ability of 4-aminopyridine and 3,4-diaminopyridine to cross the blood-brain barrier can account for their difference in toxicity","volume-title":"Aminopyridines and similarly acting drugs: Effects on nerves, muscles and synapses. Advances in the Biosciences","volume":"35","author":"Lemeignan","year":"1982"},{"issue":"22","key":"10.1002\/14651858.CD003279.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD003279.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.40.11.1109","article-title":"4-Aminopyridine - a new drug tested in the treatment of Eaton-Lambert syndrome","volume":"40","author":"Lundh","year":"1977","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003279.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(78)90409-2","article-title":"Effects of 4-aminopyridine on neuromuscular transmission","volume":"153","author":"Lundh","year":"1978","journal-title":"Brain Research"},{"issue":"7","key":"10.1002\/14651858.CD003279.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.46.7.684","article-title":"Novel drug of choice in Eaton-Lambert syndrome","volume":"46","author":"Lundh","year":"1983","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003279.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","article-title":"Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome","volume":"88","author":"Lundh","year":"1993","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD003279.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","article-title":"Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes","volume":"61","author":"Molg\u00f3","year":"1980","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003279.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert-Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003279.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","article-title":"Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin","volume":"20","author":"Muchnik","year":"1997","journal-title":"Muscle and Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003279.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.31.3.265","article-title":"Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission","volume":"31","author":"Murray","year":"1981","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003279.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"issue":"Pt 3","key":"10.1002\/14651858.CD003279.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome: a review of 50 cases","volume":"111","author":"O'Neill","year":"1988","journal-title":"Brain"},{"issue":"10","key":"10.1002\/14651858.CD003279.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.23.10.1084","article-title":"Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement","volume":"23","author":"Oh","year":"1973","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD003279.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","article-title":"Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome","volume":"20","author":"Oh","year":"1997","journal-title":"Muscle and Nerve"},{"issue":"6039","key":"10.1002\/14651858.CD003279.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/317737a0","article-title":"Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line","volume":"317","author":"Roberts","year":"1985","journal-title":"Nature"},{"issue":"9","key":"10.1002\/14651858.CD003279.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mus.880170919","article-title":"Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell cancer: correlation with the titer of anti-voltage-gated calcium channel antibody","volume":"17","author":"Takano","year":"1994","journal-title":"Muscle and Nerve"},{"issue":"12","key":"10.1002\/14651858.CD003279.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003279.pub3-BIB0043|cit43","unstructured":"UK Medicines information (UKMi) Pharmacists for NHE professionals What is the difference between amifampridine and 3,4-diaminopyridine base for Lambert-Eaton myasthenic syndrome in adults? Accessed via www.nelm.nhs.uk"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003279.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:18:25Z","timestamp":1628543905000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003279.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003279.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}